Table 8.
Invasive/Non- invasive Candidiasis (No. of Human Cases/Strains/Isolates) |
Identification Methods |
Antifungal Susceptibility |
Antifungal Resistance |
Antifungal Treatment |
Other Treatments (e.g., Probiotics, Natural Compounds, Antivirals) |
Outcome (n) |
Reference(s) |
---|---|---|---|---|---|---|---|
(invasive) Candidemia (n = 1) |
Blood culture, Vitek-2 kit |
Fluconazole, flucytosine caspofungin, voriconazole, and amphotericin B |
No | Intravenous fluconazole for 2 weeks | NA | Alive (n = 1) | [122] |
(noninvasive) Endophthalmitis (n = 1) |
Culture of anterior chamber | Intraocular amphotericin B | Topical fluconazole | Multiple intraocular amphotericin B |
Netilmicin sulfate cyclopentolate HCl eye drops | Alive (n = 1) | [135] |
(noninvasive) Dacryocystitis with cacosmia (n = 1) |
fungal hyphae observed on the excised lacrimal sac wall. DNA sequencing |
NR | NR | Antifungal agent and washing of the nasolacrimal duct | NA | Alive (n = 1) | [136] |
(invasive) Candidemia (n = 6) |
Blood culture, API-32C and Mini API system, RAPD |
2 isolates were resistant to Amphotericin B and low susceptibility to Itraconazole | Fluconazole, voriconazole, and micafungin | Amphotericin B and fluconazole |
NA | Alive (n = 5) Died (n = 1) |
[125] |
(invasive) Candidemia (n = 1) |
Blood culture, VITEC2, (ITS) region amplification and sequencing | Amphotericin B, ketoconazole, itraconazole, voriconazole, and fluconazole | No | Fluconazole and amphotericin B |
Ceftriaxone, cefepime. and oxacillin | Alive (n = 1) | [137] |
(noninvasive) Fungal keratitis (n = 1) |
Morphological characteristics and ITS region amplification and sequencing | NR | NR | Topical micafungin | No | Alive (n = 1) | [138] |
(invasive) Meningitis in HIV patient caused by C. pelliculosa (n = 1) |
Phenotypic and molecular methods, Histopathological staining(PAS) from autopsy |
NR | NR | NR | Combination antiretroviral therapy (tenofovir, abacavir and atazanavir/ritonavir) |
Died (n = 1) | [139] |
RAPD: randomly amplified polymorphic DNA; ITS: internal transcribed spacer; NA: not applicable/available; PAS: periodic acid–Schiff.